Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences develops precision therapies for genetically defined diseases, with recurring updates centered on bezuclastinib and KIT-driven disorders including Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST). News commonly covers bezuclastinib clinical data from the SUMMIT and PEAK programs, U.S. FDA New Drug Application activity, medical-meeting presentations and related business updates.
Company announcements also describe preclinical oncology programs such as CGT1263, a KRAS inhibitor candidate, and CGT4255, a brain-penetrant ErbB2/HER2 inhibitor candidate. Financial-result releases and capital updates address cash resources, at-the-market equity activity and Nasdaq inducement equity awards.
Cogent Biosciences (Nasdaq: COGT) announced promising preclinical data for bezuclastinib, a selective KIT inhibitor, at the AACR-NCI-EORTC Virtual Conference. The study highlighted bezuclastinib's effectiveness against specific KIT mutations while showing minimal brain penetration, reducing potential CNS-related side effects. The company aims to initiate three clinical trials for Advanced Systemic Mastocytosis (AdvSM), Non-Advanced Systemic Mastocytosis (NonAdvSM), and Gastrointestinal Stromal Tumors (GIST) by the end of 2021, indicating a focused approach to developing targeted treatments for genetically defined diseases.
Cogent Biosciences (Nasdaq: COGT) will present preclinical data on bezuclastinib at the AACR-NCI-EORTC Virtual International Conference from October 7-10, 2021. The poster titled 'Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V' will be available on their website shortly after 9:00 am ET on October 7.
Bezuclastinib targets the KIT D816V mutation related to systemic mastocytosis and various gastrointestinal stromal tumors. This research aims to enhance treatment options for patients with genetically driven diseases.
Cogent Biosciences (Nasdaq: COGT) announced its financial results for Q2 2021, reporting a net loss of $16.5 million, compared to $7.4 million in Q2 2020. R&D expenses surged to $12.4 million from $5.1 million year-over-year. The company initiated the Phase 2 APEX clinical study for bezuclastinib, targeting advanced systemic mastocytosis, and plans to start the SUMMIT study for non-advanced cases later in 2021. As of June 30, Cogent held $218.1 million in cash, sufficient to fund operations into 2024.
Cogent Biosciences (Nasdaq: COGT), a biotechnology firm focused on precision therapies for genetically defined diseases, will present at the Wedbush PacGrow Healthcare Conference on August 10, 2021, from 10:55 to 11:25 AM ET. CEO Andrew Robbins will lead the presentation. Attendees can access the live webcast and archived recording via the Cogent Biosciences investor relations website.
Cogent's lead therapy, bezuclastinib, targets KIT mutations linked to systemic mastocytosis and gastrointestinal stromal tumors.
Cogent Biosciences, Inc. (Nasdaq: COGT) announced that CEO Andrew Robbins will present at the Ladenburg Thalmann Virtual Healthcare Conference on July 14, 2021, from 2:00-2:25 pm ET. The event will highlight the company's focus on developing precision therapies for genetically defined diseases, including the clinical program for bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and gastrointestinal stromal tumors. Interested parties can access the live webcast and archived recording through the Cogent Biosciences investor relations website.
Cogent Biosciences, Inc. (Nasdaq: COGT) announced that its CEO, Andrew Robbins, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, from 11:30-11:55am ET. The company focuses on precision therapies for genetically defined diseases, with its lead program, CGT9486, targeting the KIT D816V mutation linked to systemic mastocytosis and gastrointestinal stromal tumors. Webcast access will be available on the Cogent investor relations website.
Cogent Biosciences, Inc. (Nasdaq: COGT) announced its financial results for Q1 2021, reporting R&D expenses of $8.2 million, down from $9.5 million in Q1 2020, attributed to a reduction in legacy trial activities. General and administrative expenses rose to $4.6 million from $3.7 million. The net loss widened to $11.7 million, compared to $6.1 million in the same period last year. The company has $230.7 million in cash, projected to support operations into 2024. Cogent also updated on its clinical trials and leadership additions, continuing its focus on precision therapies.
Cogent Biosciences (Nasdaq: COGT) appointed Evan Kearns as Chief Legal Officer on May 3, 2021. Kearns brings nearly 15 years of biopharmaceutical experience, previously serving at Agenus Inc. and Goodwin Procter LLP. He will oversee legal operations as the company prepares to initiate multiple clinical studies of CGT9486 this year, targeting genetically-driven diseases. Cogent is on track to commence three late-stage clinical trials in 2021, supported by a robust cash position, enabling the expansion of its research pipeline.
Cogent Biosciences (Nasdaq: COGT) announced the formation of the Cogent Research Team, spearheaded by new Chief Scientific Officer John Robinson, PhD. The team will focus on developing small molecule therapies for rare, genetically driven diseases. Robinson brings over 15 years of experience, having previously led teams at Pfizer and Array BioPharma. The company is set to initiate three late-stage clinical trials for its lead program, CGT9486, in 2021, supported by strong cash reserves into 2024.
Cogent Biosciences (Nasdaq: COGT) reported its financial results for Q4 2020, showing a net loss of $11.3 million, down from a net income of $2.3 million in Q4 2019. R&D expenses were $6.1 million for the quarter, while G&A expenses totaled $5.3 million. Despite these losses, Cogent had cash and equivalents of $242.2 million, sufficient to support operations through 2024. The company plans to initiate clinical trials for CGT9486 in systemic mastocytosis and GIST in 2021, supported by an upsized public offering that raised approximately $115 million.